Drug shortages in Canada: Data for 2016–2017 and perspectives on the problem

Videau, Manon; Lebel, Denis; Bussières, Jean-François

doi:10.1016/j.pharma.2018.11.007

Cited by 21 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Shortages of medicines have been on the rise globally this century (Gray and Manasse, 2012; American Society of Health-System Pharmacists, 2014; The Society of Hospital Pharmacists of Australia, 2017; Root, 2018;Miljkovic et al, 2019;Videau et al, 2019). Due to their multifaceted nature, there are currently over 26 definitions of medicine shortages from manufacturers, wholesalers, regulators, and healthcare providers (De Weerdt et al, 2015;Fox and McLaughlin, 2018).…”

Section: Introductionmentioning

confidence: 99%

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications

et al. 2020

View full text Add to dashboard Cite

Results: The participants (61.7%) are aware of the use of risk assessment procedures as a coping strategy for medicine shortages, and named the particular risk assessment procedure they are familiar with failure mode and effect analysis (FMEA) (26.4%), root cause analysis (RCA) (23.5%), the healthcare FMEA (HFMEA) (14.7%), and the hazard analysis and critical control point (HACCP) (14.7%). Only 29.4% report risk assessment as integrated into mitigation strategy protocols. Risk assessment is typically conducted within multidisciplinary teams (35.3%). Whereas 14.7% participants were aware of legislation stipulating risk assessment implementation in shortages, 88.2% claimed not to have reported their findings to their respective official institutions. 85.3% consider risk assessment a useful mitigation strategy. Conclusion: The study indicates a lack of systematically organized tools used to prospectively analyze clinical as well as operationalized risk stemming from medicine shortages in healthcare. There is also a lack of legal instruments and sufficient data confirming the necessity and usefulness of risk assessment in mitigating medicine shortages in Europe.

show abstract

Section: Introductionmentioning

confidence: 99%

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The groups of medicines, which were most frequently reported to be in shortage, were the cardiovascular medicines in Canada and Belgium; nervous system medicines in Australia, China, and Israel; and anti-infective medicines for most of the countries in South America (Bogaert et al, 2015; Yang et al, 2016; ISAGS, 2017; Schwartzberg et al, 2017; Videau et al, 2019).…”

Section: Resultsmentioning

confidence: 99%

“…In addition, by using free terms in the search strategies, we found definitions for one more region, North America (Canada and the United States), and for one country, Australia ( Table 4 ). There are two primary sources of definitions: one from health authority agency websites (Argentina, Australia, Brazil, Colombia, Spain, US, Uruguay, Norway), and the other is the published literature for countries including Belgium, Canada, France, Greece, Hungary, and Italy (Bogaert et al, 2015; Bocquet et al, 2017; Bochenek et al, 2018; Videau et al, 2019).…”

Section: Resultsmentioning

confidence: 99%

“…Both publications emphasized the urgent need to explore further the phenomena to identify mechanisms which introduce possible solutions for situations affected by medicine shortages, as well as facilitate the monitoring and assessing of signals and subsequent actions. However, there is a need to consolidate current findings to provide additional direction given current concerns, building on the experiences of other countries including Australia, Canada and the United States, as well as more recent research findings (Gupta and Huang, 2013; The Society of Hospital Pharmacists of Australian, SHPA, 2017; Videau et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

“…Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al, 2010; Gupta and Huang, 2013; Godman et al, 2014; Moon et al, 2014; Godman et al, 2015; Moorkens et al, 2017; The Society of Hospital Pharmacists of Australian, SHPA, 2017; Godman et al, 2018; Kwon et al, 2018; Videau et al, 2019). Lessons can be drawn from cross-country comparisons, even if a given country’s characteristics do not perfectly correspond in terms of geographical location, size, demography, economy, or type of health care system.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Medicine Shortages: Gaps Between Countries and Global Perspectives

et al. 2019

View full text Add to dashboard Cite

Introduction: Over the last decade, global health policies and different research areas have focused on the relevance and impact of medicine shortages. Published studies suggest there have been difficulties with access to medicines since the beginning of the 20th century, and there have been advances in our understanding and management of the problem since then. However, in view of global and regional health care concerns with shortages, we believe this phenomenon needs to be characterized and described more fully regarding the types of medicines affected, possible causes, and potential strategies to address these. The aim of this scoping review was to identify, compare if possible, and characterize the recent literature regarding the situation of medicines shortages between countries, and provide different perspectives, including a global context and national approaches. Methodology: A scoping study presented as a narrative review of the situation and findings principally based on published articles. Results: Based on the reported cases in the literature, a typology of medicines shortage and supply interruption episodes and their causes were proposed; national approaches to notify and manage the medicines shortages cases were described and classified by update frequency; principal differences between market and supply chain management perspectives of the situation were identified and global and countries’ perspectives were described. Conclusion: Policy makers require solutions that prevent those cases in which the population’s health is affected by episodes of medicine shortages and/or interruption in the supply chain. There is also a need to generate a glossary related to logistics management and the availability of medicines which will be useful to understand and overcome shortages. In addition, recognize that potential solutions are not only related with actions linked to research, development and innovation, but much wider. Overall, we believe this article can act as a basis for future discussions in this important area.

show abstract